The share price of Neurophet, an artificial intelligence (AI) company specializing in the diagnosis and treatment of brain diseases, surged 19% compared to the previous day. Neurophet has taken its first full-fledged step into the U.S. market by signing a software supply contract with the University of Washington in the United States.


[Market Focus] Neurophet Jumps 19% After Signing Contract With University Of Washington View original image

As of 9:27 a.m. on the 10th, Neurophet was trading at 32,250 won, up 19.44% (5,250 won) from the previous day.


Neurophet announced the same day that it had signed a supply contract with the University of Washington for its Neurophet Aqua and Neurophet Scale PET solutions. Neurophet Aqua is a brain neurodegeneration imaging analysis software that performs ultrafast quantitative analysis of a patient’s brain magnetic resonance imaging (MRI) scans to assess brain atrophy and white matter degeneration. It quantifies brain atrophy and white matter degeneration observed in neurodegenerative diseases such as Alzheimer’s disease and vascular dementia, and provides user-customized analysis reports.


Neurophet Scale PET is a positron emission tomography (PET) image quantitative analysis software. It automatically provides standardized uptake value ratio (SUVR) measurements for PET tracers that target a wide range of brain imaging biomarkers, including amyloid-beta protein and tau protein, which are biomarkers of Alzheimer’s disease, as well as fluorodeoxyglucose (FDG), dopamine, and others.



This contract marks the first visible achievement signaling Neurophet’s entry into the U.S. market, following the establishment of its U.S. subsidiary in October last year and the recruitment of Josh Cohen as Head of Americas Business in December of the same year.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing